Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit [n] uril EA Appel, MJ Rowland, XJ Loh, RM Heywood, C Watts, OA Scherman Chemical communications 48 (79), 9843-9845, 2012 | 100 | 2012 |
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone SGM Piccirillo, I Spiteri, A Sottoriva, A Touloumis, S Ber, SJ Price, ... Cancer research 75 (1), 194-202, 2015 | 68 | 2015 |
Characteristics and outcome of patients with DNACPR orders in an acute hospital; an observational study ZBMC Fritz, RM Heywood, SC Moffat, LE Bradshaw, JP Fuld Resuscitation 85 (1), 104-108, 2014 | 36 | 2014 |
The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/HtrA2 F Maus, D Sakry, F Binamé, K Karram, K Rajalingam, C Watts, ... PLoS One 10 (9), e0137311, 2015 | 31 | 2015 |
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, ... Journal for immunotherapy of cancer 10 (7), 2022 | 24 | 2022 |
A review of the role of stem cells in the development and treatment of glioma RM Heywood, HJ Marcus, DJ Ryan, SGM Piccirillo, TMF Al-Mayhani, ... Acta neurochirurgica 154, 951-969, 2012 | 24 | 2012 |
A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR TF Al-Mayhani, RM Heywood, V Vemireddy, JD Lathia, SGM Piccirillo, ... Neuro-oncology 21 (6), 719-729, 2019 | 16 | 2019 |
Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study A Kawsar, C Edwards, P Patel, RM Heywood, A Gupta, J Mann, ... British Journal of Dermatology 187 (6), 981-987, 2022 | 15 | 2022 |
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities SH Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, ... European Journal of Cancer 164, 62-69, 2022 | 4 | 2022 |
1047P efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM) P Bhave, T Ahmed, AN Shoushtari, A Zaremba, JM Versluis, J Mangana, ... Annals of Oncology 32, S876-S877, 2021 | 3 | 2021 |
Checkpoint inhibitor associated bullous cutaneous adverse immune-related events: a multicentre observational study A Kawsar, C Edwards, CA Harwood, R Matin, PC Lorigan, C Harland, ... | | 2022 |
73P Characteristics and outcomes of emergency presentations due to immune-mediated toxicities S Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, T Cooksley, ... Annals of Oncology 32, S1403-S1404, 2021 | | 2021 |
P14. 70 BMScope: A systematic mapping review of brain/leptomeningeal metastasis clinical studies from 2010 to 2020 VWT Cheng, R Heywood, R Zakaria, R Burger, A Fitzpatrick, K Zucker, ... Neuro-Oncology 23 (Supplement_2), ii51-ii51, 2021 | | 2021 |
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. SHE Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, ... Journal of Clinical Oncology 39 (15_suppl), 6586-6586, 2021 | | 2021 |
NG2/CSPG4 promotes proliferation and resistance to therapy in glioblastoma multiforme RM Heywood, C Watts Annals of Medicine and Surgery 3 (1), 18, 2014 | | 2014 |
NG2/CSPG4 promotes progression of glioblastoma multiforme by enhancing proliferation and resistance to therapy RM Heywood University of Cambridge, 2014 | | 2014 |
NG2/CSPG4 promotes resistance to therapy in glioblastoma multiforme R Heywood, C Watts EUROPEAN JOURNAL OF CANCER 49, S784-S784, 2013 | | 2013 |
The human sub-ependymal zone harbors glioblastoma precursors and represents a distinct therapeutic target. SGM Piccirillo, I Spiteri, A Sottoriva, A Touloumis, S Ber, SJ Price, ... Cancer Research 73 (8_Supplement), 5016-5016, 2013 | | 2013 |